Cargando…

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand

BACKGROUND: Prophylactic factor replacement therapy is recommended over on-demand treatment for preserving long-term joint health in hemophilia. Extended half-life products, including efmoroctocog alfa/eftrenonacog alfa (recombinant factor VIII [FVIII]/FIX Fc fusion proteins; herein rFVIIIFc/rFIXFc)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Álvarez-Román, María-Teresa, Shapiro, Amy D., Ragni, Margaret V., Palmborg, Helena, Bystrická, Linda, Szamosi, Johan, Casiano, Sandra, Chambost, Hervé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502440/ https://www.ncbi.nlm.nih.gov/pubmed/37720484 http://dx.doi.org/10.1016/j.rpth.2023.102163

Ejemplares similares

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
por: Giraud, Romain, et al.
Publicado: (2021)

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
por: Georgescu, Maria T., et al.
Publicado: (2020)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
por: O’Donovan, Mairead, et al.
Publicado: (2021)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein
por: McCue, J, et al.
Publicado: (2014)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
por: Oldenburg, Johannes, et al.
Publicado: (2019)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
por: Bullement, Ash, et al.
Publicado: (2019)

Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III trials using patient-reported outcomes
por: Astermark, Jan, et al.
Publicado: (2023)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand
por: Mehta, Darshan A., et al.
Publicado: (2016)

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
por: Sommer, J M, et al.
Publicado: (2014)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

Half-life–extended recombinant coagulation factor IX–albumin fusion protein is recycled via the FcRn-mediated pathway
por: Chia, Jenny, et al.
Publicado: (2018)

Real‐world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples
por: Sommer, Jurg M., et al.
Publicado: (2020)

Omani experience with the use of factor IX Fc fusion protein
por: Alzadjali, Shireen I, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dt433e5sc8m62t4p38fpnt7ppn